Evidence map›Paper›PMID 25422088›Full record

ReviewActa physiologica (Oxford, England)2015

The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.

D Ganea, K M Hooper, W Kong

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta physiologica (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Future targets for migraine treatment beyond CGRP.The journal of headache and pain · 2023
    Review
  17. Review
  18. Article
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

D GaneaDepartment of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA, USA.
K M Hooper
W Kong
Temple University · US

Funding

REGULATION OF IMMUNE CELL APOPTOSIS BY NEUROPEPTIDESR01AI047325 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI GANEA, DOINA · 2001 to 2014
$3.8M
NIAID NIH HHS R01 AI047325NIAID NIH HHS R01AI47325
6 · The paper itself

Abstract

Neuropeptides represent an important category of endogenous contributors to the establishment and maintenance of immune deviation in the immune-privileged organs such as the CNS and in the control of acute inflammation in the peripheral immune organs. Vasoactive intestinal peptide (VIP) is a major immunoregulatory neuropeptide widely distributed in the central and peripheral nervous system. In addition to neurones, VIP is synthesized by immune cells which also express VIP receptors. Here, we review the current information on VIP production and VIP-receptor-mediated effects in the immune system, the role of endogenous and exogenous VIP in inflammatory and autoimmune disorders and the present and future VIP therapeutic approaches.

Indexed as

AnimalsAutoimmune DiseasesHumansInflammationNeuropeptidesReceptors, Vasoactive Intestinal PeptideT-LymphocytesVasoactive Intestinal PeptideNeuropeptidesReceptors, Vasoactive Intestinal PeptideVasoactive Intestinal Peptideautoimmune diseasesinnate immunityneuropeptidesT-cell differentiationtolerogenic dendritic cellsvasoactive intestinal peptide

Identifiers

PMID25422088
PMCPMC4484298
OpenAlexW2029043449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.